Last reviewed 2026-04-23 · How we verify

Placebo (for Isradipine)

Placebo has no active pharmacological mechanism; it is an inert control substance used in clinical trials.

Placebo has no active pharmacological mechanism; it is an inert control substance used in clinical trials. Used for Control arm in Phase 3 trial for Parkinson's disease (isradipine comparison).

At a glance

Mechanism of action

Placebo serves as a negative control in randomized controlled trials to establish the efficacy of the active drug (isradipine) by comparison. Any therapeutic effects observed in the placebo group are attributed to natural disease progression, regression to the mean, or the placebo effect itself. This allows researchers to isolate the true pharmacological benefit of isradipine.

Approved indications

• Control arm in Phase 3 trial for Parkinson's disease (isradipine comparison)

Common side effects

No common side effects on file.

Key clinical trials

• Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation (EARLY_PHASE1)
• Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials
• Efficacy of Isradipine in Early Parkinson Disease (PHASE3)
• Improving Buprenorphine Detoxification Outcomes With Isradipine (PHASE1, PHASE2)
• Adjunctive Isradipine for the Treatment of Bipolar Depression (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Placebo (for Isradipine) CI brief — competitive landscape report
• Placebo (for Isradipine) updates RSS · CI watch RSS
• University of Rochester portfolio CI